Heartseed Inc 219A
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥2,738.00
- Day Range
- ¥2,678.00–2,772.00
- 52-Week Range
- ¥1,365.00–2,930.00
- Bid/Ask
- ¥2,693.00 / ¥2,697.00
- Shares Outstanding
- 22.90M
- Market Cap
- ¥61.69B
- Volume/Avg
- 265,000 / 400,589
Key Statistics
- Price/Earnings (Normalized)
- 218.37
- Price/Sales
- 20.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Heartseed Inc is a Japanese biotechnology company focused on developing and commercializing regenerative medicine treatments for severe heart failure. The company's product candidate, HS-001, involves transplanting clusters of purified heart muscle cells derived from iPSCs to the patient's heart to treat heart failure, especially Heart Failure with reduced Left Ventricular Ejection Fraction (HFrEF), including conditions such as Dilated Cardiomyopathy, Old Myocardial Infarction, and Dilated phase of Hypertrophic Cardiomyopathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 45
- Website
- https://www.heartseed.jp
Valuation
|
Metric
|
219A
|
|---|---|
Price/Earnings (Normalized) | 218.37 |
Price/Book Value | 9.41 |
Price/Sales | 20.85 |
Price/Cash Flow | 339.85 |
Price/Earnings
219A
Financial Strength
|
Metric
|
219A
|
|---|---|
Quick Ratio | 29.58 |
Current Ratio | 30.13 |
Interest Coverage | — |
Quick Ratio
219A
Profitability
|
Metric
|
219A
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
219A
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^Cp@YpT | LOCK|?#r$c | $126B | |||
| Moderna Inc
MRNA
| LOCK|lPv&!% | LOCK|Xg | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^fg@Lkh | LOCK|@x#z | $80B | |||
| argenx SE ADR
ARGX
| LOCK|zD&pLZ | LOCK|Z^> | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|DF>$!Pv | LOCK|LzR | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?x!xCv | LOCK|^!xR$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<>@&>Kk< | LOCK|@J&B | $26B | |||
| Incyte Corp
INCY
| LOCK|>?%s&@ | LOCK|FdX | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lMm&hHS | LOCK|F<# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<rfT!q> | LOCK|^H% | $14B |
United States